This segment focuses on the research and development of novel therapies for retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and diabetic retinopathy. Research and development activities include the formulation and clinical testing of GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib. The technology utilizes microparticle drug delivery systems to provide sustained release of therapeutic agents within the eye. This approach aims to reduce the frequency of injections and improve patient outcomes by maintaining therapeutic drug levels over extended periods. The segment addresses significant unmet medical needs in ophthalmology, offering potential improvements in vision and quality of life for patients. Market positioning is based on innovative drug delivery and sustained release technology. Future opportunities include expanding the pipeline to address other retinal diseases and exploring combination therapies. Clinical trials and regulatory aspects are crucial for advancing product candidates through the development pipeline. Partnerships with research institutions and biotech firms are essential for drug development.

This segment is dedicated to the development of treatments for glaucoma, a leading cause of irreversible blindness. The primary focus is on GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor. Research and development efforts concentrate on optimizing the formulation and delivery of the drug to effectively lower intraocular pressure (IOP), the primary risk factor for glaucoma progression. The technology involves sustained-release implants designed to provide long-term therapeutic effects, potentially reducing the need for frequent eye drops or other interventions. This segment addresses a critical need for improved glaucoma management, aiming to preserve vision and enhance patient outcomes. Market positioning is based on the development of innovative, long-acting glaucoma treatments. Future opportunities include expanding the product pipeline to address different types of glaucoma and exploring combination therapies. Regulatory and clinical aspects are critical for obtaining approvals and demonstrating the safety and efficacy of the treatments. Partnerships with ophthalmology specialists and research institutions are essential for clinical trials and product development.